Phase I Evaluation of Desbutyihalofantrine in Healthy Volunteers.

Abstract

Halofantrine HCl is an antimalarial drug approved by the FDA for the treatment of mild to moderate malaria caused by Plasm odium falciparum or Plasm odium vivax(l). The present study was designed to investigate the safety, tolerance and pharmacokinetics of halofantrine HCI given in multiple doses in a Phase I study as part of the overall development of halofantrine as a prophylactic antimalarial drug.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 1998
Accession Number
ADA364317

Entities

People

  • Darrell R. Abernethy

Organizations

  • Georgetown University

Tags

DTIC Thesaurus Topics

  • Antimalarials
  • Blood
  • Cardiovascular Physiological Phenomena
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Health Services
  • Heart Rate
  • Malaria
  • Materials
  • Pharmaceutical Preparations
  • Side Effects
  • Steady State
  • Test And Evaluation
  • Therapy
  • Vital Signs
  • Volunteers

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Parasitology and Pharmacology of Malaria.